Soleno Therapeutics (SLNO) | Stock Overview & Key Data
Soleno Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $56.50
High: $60.29
on October 3, 2025
52 Week Range
Low: $41.50
High: $90.32
on January 15, 2025
on July 9, 2025
All-Time High: $742.50 on March 2, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.4B
EPS
-4.22
P/E Ratio (TTM)
-13.52
Forward P/E
-26.08
P/B Ratio
12.44
PEG Ratio
0.16
Div. Yield
N/A
ROE
-69.53%
Beta
-2.748
Debt to Equity
21.97
Financial Highlights
Profitability
Gross Margin
97.87%
Operating Margin
-16.61%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-36.60%
Return on Equity (TTM)
-69.53%
EBITDA
$-184.3M
Net Income (TTM)
$-181.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.71
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Soleno Therapeutics SLNO | 3.40B Mid-cap | -8.85% | -11.55% | -31.67% | -17.95% | 29.53% | 19.30% | 3,695.51% | 95.41% |
| Vertex VRTX | 103.40B Large-cap | 4.55% | 1.68% | -12.25% | -16.68% | -0.61% | -11.42% | 36.61% | 49.40% |
| Regeneron REGN | 63.78B Large-cap | 6.40% | 6.42% | 9.62% | -1.74% | -16.11% | -40.76% | -16.94% | -0.34% |
| Madrigal MDGL | 9.87B Mid-cap | 4.43% | 1.78% | 48.23% | 35.44% | 41.18% | 112.57% | 490.44% | 241.88% |
| Bio-Techne TECH | 9.80B Mid-cap | 21.41% | 18.02% | 18.46% | 14.75% | -11.93% | -15.82% | -14.93% | -5.01% |
| Corcept Therapeutics CORT | 9.29B Mid-cap | 5.10% | 23.56% | 21.97% | 11.06% | 76.41% | 94.03% | 232.89% | 380.38% |
Ownership & Short Interest
Insider Ownership
1.79%
Institutional Ownership
109.55%
Shares Short
7M
Short Ratio
3.63
Short % of Shares Outstanding
15.57%
Average 10-Day Volume
2M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SLNO's 52-week high and low?
- In the last 52 weeks, Soleno Therapeutics reached a high of $90.32 (on July 9, 2025) and a low of $41.50 (on January 15, 2025).
- What is the market cap and P/E ratio for SLNO?
- Curious about Soleno Therapeutics's size and valuation? Its market capitalization stands at 3.40B. When it comes to valuation, the P/E ratio (trailing twelve months) is -13.52, and the forward P/E (looking ahead) is -26.08.
- Does SLNO pay dividends? If so, what's the yield?
- As for dividends, Soleno Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Soleno Therapeutics's main competitors or similar companies to consider before investing?
When looking at Soleno Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX103.40B Healthcare Biotechnology -11.42% 36.61% Regeneron
REGN63.78B Healthcare Biotechnology -40.76% -16.94% Madrigal
MDGL9.87B Healthcare Biotechnology 112.57% 490.44% Bio-Techne
TECH9.80B Healthcare Biotechnology -15.82% -14.93% Corcept Therapeutics
CORT9.29B Healthcare Biotechnology 94.03% 232.89% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Soleno Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Soleno Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -69.53%, the Debt to Equity ratio from the most recent quarter is 21.97, and its Gross Profit Margin stands at 97.87%.
- What is the recent revenue and earnings growth for SLNO?
- Looking at Soleno Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $33M. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of SLNO stock is held by insiders and institutions?
- Wondering who owns Soleno Therapeutics stock? Company insiders (like executives and directors) hold about 1.79% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 109.55%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.